Terms: = Pancreatic cancer AND FH, HLRCC, 2271, ENSG00000091483, MCUL1, MCL, LRCC, P07954
152 results:
1. pancreatic Metastasectomy for Secondary Malignancy of the Pancreas: A Single-institution Experience.
Lee O; Yoon SK; Yoon SJ; Kim H; Han IW; Heo JS; Shin SH
Anticancer Res; 2024 Feb; 44(2):703-710. PubMed ID: 38307567
[TBL] [Abstract] [Full Text] [Related]
2. Acute mast cell leukemia without KIT D816V mutation and lack of CD2 and CD25-a case report of rare entity.
Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
[TBL] [Abstract] [Full Text] [Related]
3. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
[TBL] [Abstract] [Full Text] [Related]
4. BH3 mimetics and azacitidine show synergistic effects on juvenile myelomonocytic leukemia.
Wu Y; Zehnle PMA; Rajak J; Koleci N; Andrieux G; Gallego-Villar L; Aumann K; Boerries M; Niemeyer CM; Flotho C; Bohler S; Erlacher M
Leukemia; 2024 Jan; 38(1):136-148. PubMed ID: 37945692
[TBL] [Abstract] [Full Text] [Related]
5. Predicting futility of upfront surgery in perihilar cholangiocarcinoma: Machine learning analytics model to optimize treatment allocation.
Ratti F; Marino R; Olthof PB; Pratschke J; Erdmann JI; Neumann UP; Prasad R; Jarnagin WR; Schnitzbauer AA; Cescon M; Guglielmi A; Lang H; Nadalin S; Topal B; Maithel SK; Hoogwater FJH; Alikhanov R; Troisi R; Sparrelid E; Roberts KJ; Malagò M; Hagendoorn J; Malik HZ; Olde Damink SWM; Kazemier G; Schadde E; Charco R; de Reuver PR; Groot Koerkamp B; Aldrighetti L;
Hepatology; 2024 Feb; 79(2):341-354. PubMed ID: 37530544
[TBL] [Abstract] [Full Text] [Related]
6. Bcl-2 family inhibitors sensitize human cancer models to therapy.
Valentini E; Di Martile M; Brignone M; Di Caprio M; Manni I; Chiappa M; Sergio I; Chiacchiarini M; Bazzichetto C; Conciatori F; D'Aguanno S; D'Angelo C; Ragno R; Russillo M; Colotti G; Marchesi F; Bellone ML; Dal Piaz F; Felli MP; Damia G; Del Bufalo D
Cell Death Dis; 2023 Jul; 14(7):441. PubMed ID: 37460459
[TBL] [Abstract] [Full Text] [Related]
7. A pancreatic Collision Tumor Comprising Mantle Cell Lymphoma and Adenocarcinoma: A Case Report and Literature Review.
Sugaya R; Taniguchi A; Abe M; Ozawa I; Kirito K; Hatakeyama S
Intern Med; 2024 Feb; 63(4):553-558. PubMed ID: 37380453
[TBL] [Abstract] [Full Text] [Related]
8. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
Perurena N; Lock R; Davis RA; Raghavan S; Pilla NF; Ng R; Loi P; Guild CJ; Miller AL; Sicinska E; Cleary JM; Rubinson DA; Wolpin BM; Gray NS; Santagata S; Hahn WC; Morton JP; Sansom OJ; Aguirre AJ; Cichowski K
Cell Rep Med; 2023 Apr; 4(4):101007. PubMed ID: 37030295
[TBL] [Abstract] [Full Text] [Related]
9. Bioactive Piperazic Acid-Bearing Cyclodepsipeptides, Lydiamycins E-H, from an Endophytic
Wang W; Kim S; Vu THN; Quach NT; Oh E; Park KH; Park C; Cho Y; Jang H; Roh E; Lee J; Kang E; Han S; Phi QT; Kang H
J Nat Prod; 2023 Apr; 86(4):751-758. PubMed ID: 36812487
[TBL] [Abstract] [Full Text] [Related]
10. Design, synthesis and biological evaluation of 2-((4-sulfamoylphenyl)amino)-pyrrolo[2,3-d]pyrimidine derivatives as CDK inhibitors.
Yang B; Quan Y; Zhao W; Ji Y; Yang X; Li J; Li Y; Liu X; Wang Y; Li Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2169282. PubMed ID: 36656085
[TBL] [Abstract] [Full Text] [Related]
11. The antitumor effect of the novel agent mcl/ACT001 in pancreatic ductal adenocarcinoma.
Yang J; Li Y; Han X; Pei X; Lin Z; Li C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5717-5728. PubMed ID: 36547690
[TBL] [Abstract] [Full Text] [Related]
12. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract] [Full Text] [Related]
13. Hypoxia-Inducible Factor 2 Alpha (HIF2α) Inhibitors: Targeting Genetically Driven Tumor Hypoxia.
Toledo RA; Jimenez C; Armaiz-Pena G; Arenillas C; Capdevila J; Dahia PLM
Endocr Rev; 2023 Mar; 44(2):312-322. PubMed ID: 36301191
[TBL] [Abstract] [Full Text] [Related]
14. Exosomal glypican-1 is elevated in pancreatic cancer precursors and can signal genetic predisposition in the absence of endoscopic ultrasound abnormalities.
Moutinho-Ribeiro P; Batista IA; Quintas ST; Adem B; Silva M; Morais R; Peixoto A; Coelho R; Costa-Moreira P; Medas R; Lopes S; Vilas-Boas F; Baptista M; Dias-Silva D; Esteves AL; Martins F; Lopes J; Barroca H; Carneiro F; Macedo G; Melo SA
World J Gastroenterol; 2022 Aug; 28(31):4310-4327. PubMed ID: 36159010
[TBL] [Abstract] [Full Text] [Related]
15. Simultaneous inhibition of Chk1 and Bcl-xL induces apoptosis
Morimoto Y; Takada K; Takeuchi O; Watanabe K; Hirohara M; Masuda Y
J Chemother; 2023 Sep; 35(5):435-447. PubMed ID: 36134604
[TBL] [Abstract] [Full Text] [Related]
16. Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
Minoura Y; Takahashi M; Maeda H; Kuwahara S; Tachikawa H; Yamamoto M; Tomioka N; Watanabe K; Sakurai A
Breast Cancer; 2022 Sep; 29(5):808-813. PubMed ID: 35641852
[TBL] [Abstract] [Full Text] [Related]
17. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy.
Ling X; Wu W; Aljahdali IAM; Liao J; Santha S; Fountzilas C; Boland PM; Li F
Clin Transl Med; 2022 May; 12(5):e881. PubMed ID: 35604033
[TBL] [Abstract] [Full Text] [Related]
18. Intraductal tubulopapillary neoplasm (ITPN) of the pancreas: a distinct entity among pancreatic tumors.
Paolino G; Esposito I; Hong SM; Basturk O; Mattiolo P; Kaneko T; Veronese N; Scarpa A; Adsay V; Luchini C
Histopathology; 2022 Sep; 81(3):297-309. PubMed ID: 35583805
[TBL] [Abstract] [Full Text] [Related]
19. The Novel, Orally Bioavailable CDK9 Inhibitor Atuveciclib Sensitises pancreatic cancer Cells to TRAIL-induced Cell Death.
Ruff JP; Kretz AL; Kornmann M; Henne-Bruns D; Lemke J; Traub B
Anticancer Res; 2021 Dec; 41(12):5973-5985. PubMed ID: 34848451
[TBL] [Abstract] [Full Text] [Related]
20. Overcoming Gemcitabine Resistance in pancreatic cancer Using the BCL-X
Thummuri D; Khan S; Underwood PW; Zhang P; Wiegand J; Zhang X; Budamagunta V; Sobh A; Tagmount A; Loguinov A; Riner AN; Akki AS; Williamson E; Hromas R; Vulpe CD; Zheng G; Trevino JG; Zhou D
Mol Cancer Ther; 2022 Jan; 21(1):184-192. PubMed ID: 34667112
[TBL] [Abstract] [Full Text] [Related]
[Next]
